“We are developing technologies that provide precise control over electric signaling in cells, offering new opportunities to treat chronic pain, inflammation, and other debilitating conditions such as cancer.”
— Erik A. Nilsen, PhD, Chief Technology Officer, Electrome
Introduction
Cancer remains one of the most persistent and devastating health challenges, with its complexity rooted not only in genetic mutations but also in profound alterations of cellular physiology and tissue microenvironments (1,2,3). In recent years, oncology has expanded beyond molecular and immunologic analysis to include the electrical properties of tumors (1,2,4). From membrane potentials to tumor-treating fields, a new frontier is emerging: electricity as both diagnostic signal and therapeutic weapon.
Electrome is positioned at the center of this transformation. By uniting fundamental biophysics with clinical translation, the company is advancing therapies that promise to be more precise, less toxic, and more adaptable than conventional cancer care.
Cancer and the bioelectric revolution
Every cell maintains an electrical potential across its membrane, regulating communication, tissue organization, growth, and repair (1,3). Cancer cells disrupt these patterns. Altered voltage gradients, dysfunctional ion channels, and abnormal gap junctions fuel unchecked proliferation, metastasis, angiogenesis, and even immune evasion (1,5).
Recent advances confirm that modulating these electrical fingerprints can restore tissue architecture, suppress tumor growth, and sensitize cancers to drugs, radiation, and immune attack (1,4,5). The idea that tumor bioelectricity drives malignancy is no longer speculation—it is a growing paradigm for cancer biology.
How bioelectric modulation disrupts cancer
Among the most promising technologies is modulated electro-hyperthermia (mEHT). This approach applies targeted radiofrequency currents to exploit the distinct electrical and metabolic properties of tumors (2). Because malignant cells differ from healthy cells in conductivity, capacitance, and energy metabolism, mEHT can selectively deliver energy to tumor sites while sparing surrounding tissue.
mEHT combines thermal and nonthermal mechanisms. Localized heating disrupts membrane integrity, ion channels, and protein function, promoting cell death and increasing tumor sensitivity to chemotherapy and radiation (2,6). Nonthermal effects emerge from protein polarization, altered signaling cascades, and disrupted regulatory networks, which can enhance apoptosis and immune recognition (2,6).
Electrome’s research programs map the heterogeneity of tumor electrical states and design frequency protocols to maximize disruption while minimizing collateral effects (1,2,4).
Emerging clinical technologies: Tumor Treating Fields and beyond
One breakthrough now in use is Tumor Treating Fields (TTFields), low-intensity alternating fields delivered through wearable devices. TTFields have extended survival in glioblastoma and are being studied in ovarian, pancreatic, and mesothelioma cancers (1,2,4,7). Clinical trials with TTFields, mEHT, and related technologies report improved tumor control, quality of life, and remission rates, with minimal side effects compared to systemic chemotherapy (2,4,6,7).
Even more promising are combinations of bioelectric modulation with immunotherapy, chemotherapy, and radiotherapy. These combinations heighten tumor visibility to immune cells, improve drug uptake, and disrupt DNA repair pathways (2,4,6,7). Electricity does not replace existing therapies—it amplifies them.
Scientific and engineering frontiers
Cancer’s electrical biology is dynamic. Tumors evolve new electrical states as they mutate, and regions with distinct voltage gradients coexist within the same mass, contributing to heterogeneity and treatment resistance (3,5,6). Advanced imaging, computational modeling, and AI-guided analytics now make it possible to track these shifts in real time.
Electrome’s engineering teams are developing adaptive treatment frameworks—platforms that sense tumor impedance and respond dynamically with tailored stimulation. This next-generation toolbox integrates impedance matching, real-time temperature and voltage feedback, and individualized stimulation blueprints, transforming oncology into a precision-guided science.
The role of Electrome: discovery, development, and clinical integration
Electrome partners with leading cancer centers, academic consortia, and advocacy groups to accelerate clinical translation. Its patented platforms and AI-driven models allow mapping of tumor heterogeneity, prediction of resistance, and customization of therapies.
CEO Ken Mayer frames the company’s vision:
“As we advance bioelectric medicine, we must consider the broader implications for healthcare systems, particularly in cost management and patient accessibility. The potential for substantial savings while improving care must be at the forefront of our discussions.”
Educational programs and open-data initiatives support clinician adoption, ensuring oncologists are trained to deploy these therapies safely and effectively.
Impact, economics, and the road to standard of care
Bioelectric cancer treatments promise not only survival gains but systemic benefits: reduced hospitalizations, minimized drug toxicity, outpatient delivery, and improved autonomy for patients (7,8). Analysts forecast oncology will become a leading share of the $40 billion bioelectric medicine market within the decade (8).
As TTFields and mEHT gain acceptance, Electrome is preparing for equitable global deployment, bridging gaps between advanced hospitals and resource-limited systems (1,7,8).
Future trajectories
Electrome’s pipeline includes AI-guided bioelectric prescriptions, frequency protocols tuned to tumor metabolism, integration with smart drug-delivery systems, and global data-sharing frameworks to harmonize device safety and outcomes.
Conclusion
The future of oncology will not be determined by chemistry and genetics alone. It will depend equally on our ability to map and modulate the electrical circuitry of cancer. With innovation, clinical partnerships, and patient-centered design, Electrome is forging a path toward therapies that are safer, smarter, and more individualized—ensuring electricity becomes a healing force at the core of cancer care (1,2,3,4,5,6,7,8).
References
- Bioelectronic medicines: Therapeutic potential and advancements in next-generation cancer therapy. J Control Release. 2022;349:440-456. Link
- Bioelectromagnetism for Cancer Treatment—Modulated Electro-Hyperthermia. Cancers. 2025;17(3):927. Link
- A bioelectric model of carcinogenesis, including propagation of cell depolarization. Sci Rep. 2021;11:13815. Link
- Emerging cancer therapies: targeting physiological networks with non-thermal systemic electromagnetic fields. Front Netw Physiol. 2024;4:1483401. Link
- WVU researchers investigate bioelectricity to better understand breast cancer. WVU Today. 2018. Link
- Nanotechnology and Cancer Bioelectricity: Bridging the Gap. Adv Sci (Weinh). 2023;e2304110. Link
- Bioelectricity and Cancer Conference. NCI/DCTD/NIH. 2025. Link
- Electroceuticals/Bioelectric Medicine Market to Reach $40.5 Billion Globally by 2032. Allied Market Research. 2024. Link
What Comes Next: Consciousness, Cognition & Electric Identity
In Bioelectric Science, Vol. VI, we will explore how bioelectric modulation intersects with consciousness itself. Could electrical therapies not only heal but also enhance cognition and self-awareness? Is neuroelectric intervention the next frontier in human performance?
Bioelectric Science Series Recap
Vol. I: The Future is Electric
Vol. II: The Signal Effect
Vol. III: Electric Immunity
Vol. IV: The Personalized Pulse
Vol. V: The Electric Brain
Vol. VI: The Electric Frontier in Cancer Treatment
Vol. VII: Signals of the Self — Bioelectricity, Consciousness, and Human Enhancement
Electrome: Bioelectric Science Series is published by Electrome Corporation as a frontier journal and cultural signal for the emerging field of frequency-based medicine. To collaborate, invest, or license, visit www.electrome.com.